Literature DB >> 17359496

High-level expression of secreted complex glycosylated recombinant human erythropoietin in the Physcomitrella Delta-fuc-t Delta-xyl-t mutant.

Andreas Weise1, Friedrich Altmann, Marta Rodriguez-Franco, Eric R Sjoberg, Wolfgang Bäumer, Heike Launhardt, Manfred Kietzmann, Gilbert Gorr.   

Abstract

The highly glycosylated peptide hormone erythropoietin (EPO) plays a key role in the regulation of erythrocyte maturation. Currently, marketed EPO is produced by recombinant technology in mammalian cell cultures. The complementary DNA (cDNA) for human EPO (hEPO) was transiently and stably expressed in the moss Physcomitrella patens wild-type and Delta-fuc-t Delta-xyl-t mutant, the latter containing N-glycans lacking the plant-specific, core-bound alpha1,3-fucose and beta1,2-xylose. New expression vectors were designed based on a Physcomitrella ubiquitin gene-derived promoter for the expression of hEPO cDNA. Transient expression in protoplasts was much stronger at 10 than at 20 degrees C. In Western blot analysis, the molecular size of moss-produced recombinant human EPO (rhEPO) was identified to be 30 kDa, and it accumulated in the medium of transiently transformed protoplasts to high levels around 0.5 microg/mL. Transgenic Physcomitrella Delta-fuc-t Delta-xyl-t mutant lines expressing EPO cDNA showed secretion of rhEPO through the cell wall to the culture medium. In 5- and 10-L photobioreactor cultures, secreted rhEPO accumulated to high levels above 250 microg/g dry weight of moss material after 6 days. Silver staining of rhEPO on sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) taken from the bioreactor culture demonstrated a high purity of the over-expressed secreted rhEPO, with a very low background of endogenous moss proteins. Peptide mapping of rhEPO produced by the Physcomitrella Delta-fuc-t Delta-xyl-t mutant indicated correct processing of the plant-derived signal peptide. All three N-glycosylation sites of rhEPO were occupied by complex-type N-glycans completely devoid of the plant-specific core sugar residues fucose and xylose.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17359496     DOI: 10.1111/j.1467-7652.2007.00248.x

Source DB:  PubMed          Journal:  Plant Biotechnol J        ISSN: 1467-7644            Impact factor:   9.803


  28 in total

1.  N-Glycosylation engineering of tobacco plants to produce asialoerythropoietin.

Authors:  Farooqahmed S Kittur; Chiu-Yueh Hung; Diane E Darlington; David C Sane; Jiahua Xie
Journal:  Plant Cell Rep       Date:  2012-02-28       Impact factor: 4.570

2.  On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect.

Authors:  Jianfeng Xu; Ningning Zhang
Journal:  Pharm Bioprocess       Date:  2014-12-01

3.  Glycoengineering tobacco plants to stably express recombinant human erythropoietin with different N-glycan profiles.

Authors:  Farooqahmed S Kittur; Chiu-Yueh Hung; Chuanshu Zhu; Asif Shajahan; Parastoo Azadi; Michelle D Thomas; Jackson L Pearce; Clemens Gruber; Somanath Kallolimath; Jiahua Xie
Journal:  Int J Biol Macromol       Date:  2020-04-26       Impact factor: 6.953

4.  Two-step purification procedure for recombinant human asialoerythropoietin expressed in transgenic plants.

Authors:  Farooqahmed S Kittur; Elena Arthur; Maikhanh Nguyen; Chiu-Yueh Hung; David C Sane; Jiahua Xie
Journal:  Int J Biol Macromol       Date:  2014-10-25       Impact factor: 6.953

Review 5.  Glycoprotein production in moss bioreactors.

Authors:  Eva L Decker; Ralf Reski
Journal:  Plant Cell Rep       Date:  2011-09-29       Impact factor: 4.570

6.  An Env-derived multi-epitope HIV chimeric protein produced in the moss Physcomitrella patens is immunogenic in mice.

Authors:  Lucía Orellana-Escobedo; Sergio Rosales-Mendoza; Andrea Romero-Maldonado; Juliana Parsons; Eva L Decker; Elizabeth Monreal-Escalante; Leticia Moreno-Fierros; Ralf Reski
Journal:  Plant Cell Rep       Date:  2014-12-05       Impact factor: 4.570

7.  A Novel Plant-Produced Asialo-rhuEPO Protects Brain from Ischemic Damage Without Erythropoietic Action.

Authors:  Maotao He; Farooqahmed S Kittur; Chiu-Yueh Hung; Jianhui Zhang; Li Jing; David C Sane; P Andy Li; Jiahua Xie
Journal:  Transl Stroke Res       Date:  2021-09-22       Impact factor: 6.829

8.  Plant-produced human recombinant erythropoietic growth factors support erythroid differentiation in vitro.

Authors:  Konstantin Musiychuk; Rajarajeswari Sivalenka; Jennifer Jaje; Hong Bi; Rosemary Flores; Brenden Shaw; R Mark Jones; Tatiana Golovina; Jacob Schnipper; Luipa Khandker; Ruiqiang Sun; Chang Li; Lin Kang; Vanessa Voskinarian-Berse; Xiaokui Zhang; Stephen Streatfield; John Hambor; Stewart Abbot; Vidadi Yusibov
Journal:  Stem Cells Dev       Date:  2013-05-14       Impact factor: 3.272

9.  Toward stable genetic engineering of human O-glycosylation in plants.

Authors:  Zhang Yang; Eric P Bennett; Bodil Jørgensen; Damian P Drew; Emma Arigi; Ulla Mandel; Peter Ulvskov; Steven B Levery; Henrik Clausen; Bent L Petersen
Journal:  Plant Physiol       Date:  2012-07-12       Impact factor: 8.340

10.  Perspectives on using physcomitrella patens as an alternative production platform for thapsigargin and other terpenoid drug candidates.

Authors:  Henrik Toft Simonsen; Damian Paul Drew; Christina Lunde
Journal:  Perspect Medicin Chem       Date:  2009-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.